Tag search results
Tags let us describe our content with keywords, making it easier to find what you're most interested in. Use the search box to look for tags, or explore our coverage with the lists below.
Utah is paying public employees to travel to Mexico to fill their prescription medications in a program aimed at reducing the high cost of prescription drugs.
For too long, drug companies have been price gouging seniors and hardworking Americans.
Sales of biosimilars, cheaper near-copies of pricey biologic drugs, have been so limited in the U.S. that their future is in doubt.
As Congress and President Donald Trump’s administration aim to lower prescription drug costs, outside groups like the Alliance for Patient Access are seeking to sway the outcome. But not all of these organizations are clear about who they actually represent. Their names can obscure the source of the message, and they’re cagey about where they get their funding.
Challenging President Donald Trump to make good on his pledge to cut prescription drug prices, congressional liberals proposed legislation Thursday to bring U.S. prices in line with the much lower costs in other countries.
President Trump’s plan for lowering Medicare drug costs is good, even cutting-edge. As Democrats successfully campaign on health care, Trump has come back with a proposal that could save Medicare patients and taxpayers $17.2 billion over five years. Too bad its chances of happening are close to nil. We’ve seen this talkie before. As Election Day approaches, Trump makes a promise that seems to favor the public over big-money interests. The moment the last vote is counted, it vanishes.
Insurers will no longer be able to bar pharmacists from telling consumers when paying cash would be cheaper than using insurance for their prescriptions, as a result of bills signed Wednesday by President Donald Trump.
President Donald Trump’s long-awaited plan to bring down drug prices, unveiled Friday, will mostly spare the pharmaceutical industry he previously accused of “getting away with murder” and instead focus on increasing private competition and requiring more openness about costs.
President Donald Trump’s pick for health secretary said Tuesday he’s wary of a broad government role in negotiating prescription drug prices, arguing that it may lead to reduced access for patients.
Americans agree: Prices for prescription drugs are intolerable. Why has nothing changed? Big-money lobbying is the reason. It’s time somebody looked out for consumers.
U.S. prosecutors are examining the prices of skin treatments made by Perrigo Co. and a handful of other companies as part of a sweeping criminal investigation into possible collusion in the generic drug business, according to a document filed in court this week.
If prices don’t come down, and quickly, Trump should back up his tough talk with action.
President Donald Trump told drugmakers at a White House meeting Tuesday they were charging too much and promised to get better bargains for government health programs, in addition to finding ways to get new medicines to market faster.
There are arguments over the merits and effects, but the politics are clear cut. In a Kaiser Foundation poll last autumn, the public, by 82 percent to 17 percent, favored allowing the federal government to negotiate lower drug prices.
Branded drug companies’ share of total U.S. spending on their products is declining, in part because of an increase in secret rebates paid to middlemen, according to an analysis sponsored by an industry group that’s been seeking to deflect scrutiny of rising prices.
A key feature of Republican plans to replace Obamacare is allowing market forces to boost innovation and competition among health care providers. “Unleashing the power of choice and competition is the best way to lower health care costs and improve quality,” declares House Speaker Paul Ryan in his conservative manifesto “A Better Way.”
Outspoken former pharmaceutical executive Martin Shkreli said the national outrage over drug pricing was blown out of proportion and heightened by the U.S. presidential election, although he conceded he could have predicted the criticism better.
Angered by skyrocketing drug prices, a pair of senators on Wednesday urged Congress to block companies from cornering the market on old, off-patent drugs.
The skyrocketing costs of prescription drugs has been noticeably absent from discussion in the presidential debates – even as bipartisan anger about price gouging has united Congress. But the trade group for the pharmaceutical industry, PhRMA, is gearing up to defend drug prices after the election, seeking an additional $100 million in annual dues from its members, according to a report from Politico.
A top pharmaceutical lobbying group is launching an ad campaign to defend drugmakers that have been under fire for their pricing practices.